Nanexa AB (publ) (STO:NANEXA)
3.730
+0.075 (2.05%)
Feb 10, 2026, 5:24 PM CET
Nanexa AB Revenue
Nanexa AB had revenue of 4.63M SEK in the quarter ending September 30, 2025, a decrease of -58.31%. This brings the company's revenue in the last twelve months to 31.92M, down -37.12% year-over-year. In the year 2024, Nanexa AB had annual revenue of 46.69M, down -21.07%.
Revenue (ttm)
31.92M
Revenue Growth
-37.12%
P/S Ratio
18.85
Revenue / Employee
2.13M
Employees
15
Market Cap
601.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.69M | -12.47M | -21.07% |
| Dec 31, 2023 | 59.16M | 31.99M | 117.72% |
| Dec 31, 2022 | 27.17M | 9.16M | 50.87% |
| Dec 31, 2021 | 18.01M | -2.85M | -13.66% |
| Dec 31, 2020 | 20.86M | 12.13M | 138.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 425.75M |
| Enzymatica AB | 52.73M |
| Cinclus Pharma Holding AB | 48.42M |
| Cereno Scientific AB | 46.66M |
| Newbury Pharmaceuticals AB | 36.76M |
| Orexo AB | 26.00M |
| Moberg Pharma AB | 12.50M |
| Klaria Pharma Holding AB (publ.) | 10.05M |